Combining CC-486 and Venetoclax for treating Acute Myeloid Leukemia

CC-486 and Venetoclax for Acute Myeloid Leukemia

This study is testing if a new combination of two medications, CC-486 and venetoclax, can help people with relapsed or hard-to-treat Acute Myeloid Leukemia feel better and improve their treatment outcomes.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (estimated)
• Ages: 18 Years to 100 Years
• Sex: All
• Sponsor: University of Colorado, Denver (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 2 sites (Aurora, Colorado and 1 other locations)
• Trial ID: NCT05287568 on ClinicalTrials.gov

What this trial studies

This open-label, dose escalation Phase I pilot study aims to evaluate the safety and efficacy of CC-486 (oral azacitidine) in combination with venetoclax for patients with relapsed and refractory Acute Myeloid Leukemia (AML). Eligible participants will receive venetoclax for three days, followed by CC-486 for 14 days in a 28-day cycle. The study will monitor patients for tumor lysis syndrome and perform bone marrow biopsies to assess treatment response. Once the maximum tolerated dose (MTD) is established, the study will proceed to an expansion phase using the recommended dose.

Who should consider this trial

Good fit: Ideal candidates include adults with confirmed non-APL AML who have undergone at least one line of therapy and have a projected life expectancy of at least 12 weeks.

Not a fit: Patients with acute promyelocytic leukemia (APL) or those who have not received any prior therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment combination could provide a new therapeutic option for patients with relapsed and refractory AML.

How similar studies have performed: Other studies combining venetoclax with various agents have shown promising results, indicating potential success for this approach.

Eligibility criteria

Inclusion Criteria:

1. Subject must have confirmation of non-APL AML by WHO criteria46 and have undergone at least one line of therapy (dose escalation and dose expansion R/R cohorts), or have had no prior lines of therapy (newly diagnosed cohort) Prior treatment with hydroxyurea or ATRA is allowed in the newly diagnosed cohort.
2. For the newly diagnosed cohort, subjects must be unlikely to tolerate standard intensive chemotherapy due to age, performance status, or comorbidities based on at least one of the following criteria:

   a. age ≥75 years old OR b. age \< 75 years old with at least one of the following: i. ECOG performance status of 3 ii. Cardiac history of CHF or documented EF ≤50% iii. pulmonary disease with DLCO ≤65% or FEV1 ≤65% iv. creatinine clearance ≥30 mL/min to \< 45 mL/min based on the CKD-EPI Creatinine Equation (2021). https://www.kidney.org/content/ckd-epi-creatinine-equation-2021 v. any other comorbidity that the investigator judges to be incompatible with intensive chemotherapy
3. Patients must have ECOG of 0 to 3 (if \< 75 years old) or 0 to 2 (if ≥75 years old)
4. Transplant eligible patients can participate in the study and they are allowed to proceed with stem cell transplantation at any time during the study.
5. Subject must have a projected life expectancy of at least 12 weeks.
6. Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.
7. Subject must have adequate liver function as demonstrated by:

   1. aspartate aminotransferase (AST) ≤ 3.0 × ULN\*
   2. alanine aminotransferase (ALT) ≤ 3.0 × ULN\*
   3. bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome\* \* Unless considered due to leukemic organ involvement
8. Non-sterile male subjects must use contraceptive methods with partner(s) at least prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug. No contraception is required if male subjects are surgically sterile (vasectomy with medical assessment confirming surgical success) or if the male subject has a female partner who is postmenopausal or permanently sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
9. Female subjects must be either:

   1. Postmenopausal; defined as Age \> 60 years with no menses for 12 or more months without an alternative medical cause; OR
   2. Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); OR
   3. If subject is of childbearing potential, use of contraception is required while on study treatment and for 6 months after the last dose.
10. Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed screening or procedures.
11. Subject is informed that consumption of the following fruits is prohibited 3 days prior to the initiation of study treatment and throughout participation: grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit.

Exclusion criteria:

1. Subject has known active CNS involvement from AML.
2. Subject is known to be positive for HIV. HIV testing is not required.
3. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate.
4. Subject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:

   1. Significant active cardiac disease within the previous 6 months including: New York Heart Association heart failure \> class 2, unstable angina, or myocardial infarction.
   2. Renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia.
5. Subject has a malabsorption syndrome or other condition that precludes enteral route of administration. This includes history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease (e.g. sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.
6. Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal). Uncontrolled is defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment.
7. Subject has a history of other malignancies prior to study entry, with the exception of:

   1. Adequately treated in situ carcinoma of the breast or cervix uteri
   2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
   3. Prostate cancer not requiring therapy beyond hormonal therapy
   4. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
8. Subject has a white blood cell count \> 25 × 109/L. Note: hydroxyurea or apheresis are permitted to meet this criterion.
9. Any subject who is a candidate for intensive induction therapy and agrees to receive this therapy.
10. Pregnant or breast-feeding females. A pregnancy test will be obtained at the time of screening.
11. Known or suspected hypersensitivity to azacitidine or mannitol.

Where this trial is running

Aurora, Colorado and 1 other locations

• CU Anschutz Medical Campus — Aurora, Colorado, United States (Recruiting)
• University of Colorado Hospital — Aurora, Colorado, United States (Recruiting)

Study contacts

• Principal investigator: Daniel E Pollyea, MD — University of Colorado, Denver
• Study coordinator: Derek Schatz

Conditions AML